After years of delays, the initiative's usefulness has "diminished significantly," imaging leaders from several noted institutions wrote in Health Affairs. 

The quality initiative has been pushed back several times, and some are concerned that it's no longer relevant and duplicates other efforts. 

Frank Scholz, PhD, will oversee the Beloit, Wisconsin, firm's Mo-99 expansion efforts and new radioisotope development programs, among other duties.

The findings were presented virtually during the Society of Nuclear Medicine and Molecular Imaging's 2021 Annual Meeting.

The Society of Nuclear Medicine & Molecular Imaging said it’s received “many complaints” from the field pertaining to various commercial payers. 

The American Society of Nuclear Cardiology recently met with the Louisville, Kentucky, insurer, which shared an openness to reviewing a recent coverage determination. 

With the help of Phoenix's advanced industrial imaging capabilities, the new entity hopes to ramp up its production of molybdenum-99.

The findings come by way of the RESCUE Trial, which included more than 1,000 participants from 44 different sites.